The inflammatory UPR-IFNG axis reveals LBP as a survival and immunotherapy-response marker in hepatocellular carcinoma.
A new biomarker helps identify which liver cancer patients may respond better to immunotherapy, supporting more personalized treatment selection.
BACKGROUND: Liver hepatocellular carcinoma (LIHC) remains difficult to stratify because tumor heterogeneity and an immunosuppressive microenvironment limit immune checkpoint blockade (ICB). CONCLUSIONS: This study identifies LBP as a UPR-related and IFNG-associated candidate biomarker for LIHC prognosis and immunotherapy-response stratification.
What the study was
- Study design
- Cohort Study
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Translational oncology
Why it surfaced
Matched watchlist: Precision oncology and genomic; scored 7/10 based on abstract-level review; design=Cohort Study; species=mixed; flag=PROMISING_PRELIMINARY.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.